Tsung-Kun Lin
Overview
Explore the profile of Tsung-Kun Lin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
101
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin M, Wu W, Chen Y, Chien W, Lin T, Chou Y, et al.
Cardiovasc Drugs Ther
. 2024 Dec;
PMID: 39671131
Purpose: Proton pump inhibitors (PPIs) are widely prescribed for gastrointestinal disorders. Lansoprazole, a PPI, has been recognized for its potential effects of improving insulin resistance, reduction of oxidative stress, and...
2.
Li F, Sheih Y, Lin M, Chen Y, Wu W, Lin T, et al.
BMC Cardiovasc Disord
. 2024 Nov;
24(1):628.
PMID: 39522052
Background: We explored if the administration of fluoxetine, recognized for its potential in adipocyte browning, entails a differential risk of coronary heart disease (CHD) in comparison to other SSRI medications....
3.
Lin T, Wang W, Yang T, Jong G
Cancers (Basel)
. 2024 Jun;
16(11).
PMID: 38893264
(1) Background: Recently, sodium-glucose cotransporter-2 inhibitors (SGLT2Is) have been reported to significantly reduce renal cell carcinoma (RCC) risk. However, the effect between individual SGLT2Is on RCC incidence in patients with...
4.
Huang Y, Sung M, Lin T, Kuo C, Hsu Y
J Formos Med Assoc
. 2023 Nov;
123(8):830-836.
PMID: 37919197
Oral cancer is a prevalent global issue, with oral squamous cell carcinoma constituting the majority of cases. Standard treatments like surgery, radiotherapy, and chemotherapy are available but may have adverse...
5.
Lin T, Lee M, Cheng Y, Ma T, Chen M, Yang T, et al.
Diabetol Metab Syndr
. 2023 Aug;
15(1):170.
PMID: 37592322
Background: Several observational cohorts and meta-analytical studies on humans have shown that users of sodium-glucose cotransporter-2 inhibitors (SGLT2is) have a lower risk for new-onset acute coronary syndrome (ACS) than nonusers....
6.
Jong G, Lin T, Liao P, Huang J, Yang T, Pan L
Transl Stroke Res
. 2023 Jul;
15(6):1098-1107.
PMID: 37442919
Clinical studies have investigated the effects of using sodium-glucose co-transporter-2 (SGLT2) inhibitors on the development of new-onset stroke (NOS) in patients with type 2 diabetes (T2D) and chronic kidney disease...
7.
Jong G, Lin T, Huang J, Liao P, Yang T, Pan L
Biomedicines
. 2023 May;
11(4).
PMID: 37189690
Patients with chronic kidney disease (CKD) are at a higher risk for developing dementia than the general population. Clinical studies have investigated the effects of statin use on new-onset dementia...
8.
Lin M, Wu W, Chen Y, Lin T, Chou Y, Sun C
Diabetol Metab Syndr
. 2023 May;
15(1):96.
PMID: 37165435
Background: Proton pump inhibitors (PPIs) are common and widely used for gastrointestinal-related disorders. Lansoprazole is one of PPIs with potential benefits of anti-inflammation, reduced oxidative stress, and anti-diabetes. The aims...
9.
Chang C, Chen Y, Wu W, Lin T, Chou Y, Lin M, et al.
Osteoporos Int
. 2023 Apr;
34(7):1223-1230.
PMID: 37079024
Introduction: Nifedipine was one L-type dihydropyridine calcium channel blocker (CCB) that can improve bone loss. However, epidemiological studies on the association between the use of nifedipine and osteoporosis risk are...
10.
Chung M, Chen Y, Wu W, Lin M, Yang Y, Hueng D, et al.
Int J Environ Res Public Health
. 2022 Nov;
19(22).
PMID: 36430077
Background: Proton pump inhibitor (PPI) lansoprazole acts as a liver X receptor agonist, which plays a crucial role in the crosstalk of osteoblasts and osteoclasts in vitro and during bone...